These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 22196621)

  • 1. Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.
    Pfefferkorn JA; Guzman-Perez A; Litchfield J; Aiello R; Treadway JL; Pettersen J; Minich ML; Filipski KJ; Jones CS; Tu M; Aspnes G; Risley H; Bian J; Stevens BD; Bourassa P; D'Aquila T; Baker L; Barucci N; Robertson AS; Bourbonais F; Derksen DR; Macdougall M; Cabrera O; Chen J; Lapworth AL; Landro JA; Zavadoski WJ; Atkinson K; Haddish-Berhane N; Tan B; Yao L; Kosa RE; Varma MV; Feng B; Duignan DB; El-Kattan A; Murdande S; Liu S; Ammirati M; Knafels J; Dasilva-Jardine P; Sweet L; Liras S; Rolph TP
    J Med Chem; 2012 Feb; 55(3):1318-33. PubMed ID: 22196621
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of orally active hepatoselective glucokinase activators for treatment of Type II Diabetes Mellitus.
    Xu J; Lin S; Myers RW; Trujillo ME; Pachanski MJ; Malkani S; Chen HS; Chen Z; Campbell B; Eiermann GJ; Elowe N; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; McMasters DR; Mitra K; Tong X; Xu L; Zhang F; Zhang R; Addona GH; Berger JP; Zhang B; Parmee ER
    Bioorg Med Chem Lett; 2017 May; 27(9):2063-2068. PubMed ID: 28284809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment.
    Sharma R; Litchfield J; Bergman A; Atkinson K; Kazierad D; Gustavson SM; Di L; Pfefferkorn JA; Kalgutkar AS
    Drug Metab Dispos; 2015 Feb; 43(2):190-8. PubMed ID: 25384899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of 3-(4-methanesulfonylphenoxy)-N-[1-(2-methoxy-ethoxymethyl)-1H-pyrazol-3-yl]-5-(3-methylpyridin-2-yl)-benzamide as a novel glucokinase activator (GKA) for the treatment of type 2 diabetes mellitus.
    Park K; Lee BM; Hyun KH; Lee DH; Choi HH; Kim H; Chong W; Kim KB; Nam SY
    Bioorg Med Chem; 2014 Apr; 22(7):2280-93. PubMed ID: 24588963
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of piragliatin--first glucokinase activator studied in type 2 diabetic patients.
    Sarabu R; Bizzarro FT; Corbett WL; Dvorozniak MT; Geng W; Grippo JF; Haynes NE; Hutchings S; Garofalo L; Guertin KR; Hilliard DW; Kabat M; Kester RF; Ka W; Liang Z; Mahaney PE; Marcus L; Matschinsky FM; Moore D; Racha J; Radinov R; Ren Y; Qi L; Pignatello M; Spence CL; Steele T; Tengi J; Grimsby J
    J Med Chem; 2012 Aug; 55(16):7021-36. PubMed ID: 22809456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The hepatoselective glucokinase activator PF-04991532 ameliorates hyperglycemia without causing hepatic steatosis in diabetic rats.
    Erion DM; Lapworth A; Amor PA; Bai G; Vera NB; Clark RW; Yan Q; Zhu Y; Ross TT; Purkal J; Gorgoglione M; Zhang G; Bonato V; Baker L; Barucci N; D'Aquila T; Robertson A; Aiello RJ; Yan J; Trimmer J; Rolph TP; Pfefferkorn JA
    PLoS One; 2014; 9(5):e97139. PubMed ID: 24858947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward a unified model of passive drug permeation II: the physiochemical determinants of unbound tissue distribution with applications to the design of hepatoselective glucokinase activators.
    Ghosh A; Maurer TS; Litchfield J; Varma MV; Rotter C; Scialis R; Feng B; Tu M; Guimaraes CR; Scott DO
    Drug Metab Dispos; 2014 Oct; 42(10):1599-610. PubMed ID: 25024402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic properties of the glucokinase activator MK-0941 in rodent models of type 2 diabetes and healthy dogs.
    Eiki J; Nagata Y; Futamura M; Sasaki-Yamamoto K; Iino T; Nishimura T; Chiba M; Ohyama S; Yoshida-Yoshimioto R; Fujii K; Hosaka H; Goto-Shimazaki H; Kadotani A; Ohe T; Lin S; Langdon RB; Berger JP
    Mol Pharmacol; 2011 Dec; 80(6):1156-65. PubMed ID: 21937665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of an intravenous hepatoselective glucokinase activator for the treatment of inpatient hyperglycemia.
    Stevens BD; Litchfield J; Pfefferkorn JA; Atkinson K; Perreault C; Amor P; Bahnck K; Berliner MA; Calloway J; Carlo A; Derksen DR; Filipski KJ; Gumkowski M; Jassal C; MacDougall M; Murphy B; Nkansah P; Pettersen J; Rotter C; Zhang Y
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6588-92. PubMed ID: 24239482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel, highly potent systemic glucokinase activators for the treatment of Type 2 Diabetes Mellitus.
    Xu J; Lin S; Myers RW; Addona G; Berger JP; Campbell B; Chen HS; Chen Z; Eiermann GJ; Elowe NH; Farrer BT; Feng W; Fu Q; Kats-Kagan R; Kavana M; Malkani S; McMasters DR; Mitra K; Pachanski MJ; Tong X; Trujillo ME; Xu L; Zhang B; Zhang F; Zhang R; Parmee ER
    Bioorg Med Chem Lett; 2017 May; 27(9):2069-2073. PubMed ID: 28284804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of liver-directed glucokinase activator having anti-hyperglycemic effect without hypoglycemia.
    Deshpande AM; Bhuniya D; De S; Dave B; Vyavahare VP; Kurhade SH; Kandalkar SR; Naik KP; Kobal BS; Kaduskar RD; Basu S; Jain V; Patil P; Chaturvedi Joshi S; Bhat G; Raje AA; Reddy S; Gundu J; Madgula V; Tambe S; Shitole P; Umrani D; Chugh A; Palle VP; Mookhtiar KA
    Eur J Med Chem; 2017 Jun; 133():268-286. PubMed ID: 28390958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The potential role of glucokinase activator SHP289-04 in anti-diabetes and hepatic protection.
    Lei L; Liu S; Li Y; Song H; He L; Liu Q; Sun S; Li Y; Feng Z; Shen Z
    Eur J Pharmacol; 2018 May; 826():17-23. PubMed ID: 29477658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for the design of hepatoselective glucokinase activators to treat type 2 diabetes.
    Pfefferkorn JA
    Expert Opin Drug Discov; 2013 Mar; 8(3):319-30. PubMed ID: 23289965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allosteric activators of glucokinase: potential role in diabetes therapy.
    Grimsby J; Sarabu R; Corbett WL; Haynes NE; Bizzarro FT; Coffey JW; Guertin KR; Hilliard DW; Kester RF; Mahaney PE; Marcus L; Qi L; Spence CL; Tengi J; Magnuson MA; Chu CA; Dvorozniak MT; Matschinsky FM; Grippo JF
    Science; 2003 Jul; 301(5631):370-3. PubMed ID: 12869762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of a potent glucokinase activator with a favorable liver and pancreas distribution pattern for the treatment of type 2 diabetes mellitus.
    Fujieda H; Kogami M; Sakairi M; Kato N; Makino M; Takahashi N; Miyazawa T; Harada S; Yamashita T
    Eur J Med Chem; 2018 Aug; 156():269-294. PubMed ID: 30006171
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a new class of glucokinase activators through structure-based design.
    Hinklin RJ; Boyd SA; Chicarelli MJ; Condroski KR; DeWolf WE; Lee PA; Lee W; Singh A; Thomas L; Voegtli WC; Williams L; Aicher TD
    J Med Chem; 2013 Oct; 56(19):7669-78. PubMed ID: 24015910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of cycloalkyl-fused N-thiazol-2-yl-benzamides as tissue non-specific glucokinase activators: Design, synthesis, and biological evaluation.
    Wang Z; Shi X; Zhang H; Yu L; Cheng Y; Zhang H; Zhang H; Zhou J; Chen J; Shen X; Duan W
    Eur J Med Chem; 2017 Oct; 139():128-152. PubMed ID: 28800453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Hepatic Organic Anion-Transporting Polypeptide 1B Inhibition and Chronic Kidney Disease on the Pharmacokinetics of a Liver-Targeted Glucokinase Activator: A Model-Based Evaluation.
    Bergman A; Bi YA; Mathialagan S; Litchfield J; Kazierad DJ; Pfefferkorn JA; Varma MVS
    Clin Pharmacol Ther; 2019 Oct; 106(4):792-802. PubMed ID: 30919935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Research and development of glucokinase activators for diabetes therapy: theoretical and practical aspects.
    Matschinsky FM; Zelent B; Doliba NM; Kaestner KH; Vanderkooi JM; Grimsby J; Berthel SJ; Sarabu R
    Handb Exp Pharmacol; 2011; (203):357-401. PubMed ID: 21484579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antidiabetic potential of a novel dual-target activator of glucokinase and peroxisome proliferator activated receptor-γ.
    Lei L; Liu Q; Liu S; Huan Y; Sun S; Chen Z; Li L; Feng Z; Li Y; Shen Z
    Metabolism; 2015 Oct; 64(10):1250-61. PubMed ID: 26189598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.